BIOCEPT, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-11-21: Form 8-K; Period of report 2022-11-21; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-11-18: Form 8-K; Period of report 2022-11-17; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2022-11-14: Form 8-K; Period of report 2022-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-10-19: Form 8-K; Period of report 2022-10-18; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-11-21 | 8-K | 2022-11-21 | 2.02 Results of Operations and Financial Condition | 2.02 On November 21, 2022, we issued a press release announcing our financial results for the three months ended September 30, 2022. | d423922d8k.htm |
| 2022-11-18 | 8-K | 2022-11-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 17, 2022, we appointed Quyen Dao-Haddock to our Board of Directors (the “Board”), to serve as a Class III director with a term of office expiring at our 2025 Annual Meeting of Stockholders. | d422984d8k.htm |
| 2022-11-14 | 8-K | 2022-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2022, we issued a press release announcing our financial results for the three months ended June 30, 2022. | d225527d8k.htm |
| 2022-10-19 | 8-K | 2022-10-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On October 18, 2022, Biocept, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for the 30 consecutive trading days preceding the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). | d335561d8k.htm |
| 2022-08-22 | 8-K | 2022-08-17 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On August 17, 2022, Biocept, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Form 10-Q”) in a timely manner. | d265758d8k.htm |
| 2022-07-14 | 8-K | 2022-07-14 | 7.01 Regulation FD Disclosure | 7.01 Beginning on July 14, 2022, members of the management team of Biocept, Inc. (the “Company”) may be providing presentation materials (the “Presentation”) to certain interested parties. | d346825d8k.htm |
| 2022-07-13 | 8-K | 2022-07-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 10, 2022, Biocept, Inc. (the “Company”) convened and adjourned its 2022 Annual Meeting of Stockholders (the “Annual Meeting”), without any business being conducted, due to lack of the requisite quorum being present. | d337292d8k.htm |
| 2022-06-27 | 8-K | 2022-06-24 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 As previously reported by Biocept, Inc. (the “Company”) in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 12, 2022, Mayer Hoffman McCann P.C. (“MHM”), the former independent registered public accounting firm of the Company, declined to stand for re-appointment as the independent registered public accounting firm of the Company. | d333627d8k.htm |
| 2022-06-13 | 8-K | 2022-06-10 | 8.01 Other Events | 8.01 On June 10, 2022, Biocept, Inc. convened and adjourned its 2022 Annual Meeting of Stockholders (the “Annual Meeting”), without any business being conducted, due to lack of the requisite quorum being present. | d259334d8k.htm |
| 2022-05-24 | 8-K | 2022-05-23 | 2.02 Results of Operations and Financial Condition | 2.02 On May 23, 2022, we issued a press release announcing our financial results for the three months ended March 31, 2022. | d354923d8k.htm |
| 2022-04-12 | 8-K | 2022-04-07 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On April 7, 2022, Mayer Hoffman McCann P.C. (“MHM”), the independent registered public accounting firm of Biocept, Inc. (the “Company”), notified the Company that it has decided to decline to stand for re-appointment as the independent registered public accounting firm of the Company. | d211627d8k.htm |
| 2022-04-07 | 8-K | 2022-04-06 | 2.02 Results of Operations and Financial Condition | 2.02 On April 6, 2022, we issued a press release announcing our financial results for the three months and year ended December 31, 2021. | d516159d8k.htm |
| 2022-04-01 | 8-K | 2022-03-31 | 2.02 Results of Operations and Financial Condition | 2.02 On March 31, 2022, we issued a press release announcing certain financial results for the year ended December 31, 2021. | d319160d8k.htm |
| 2022-03-24 | 8-K | 2022-03-22 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 22, 2022, the Board of Directors (the “Board”) of Biocept, Inc. (the “Company”) approved an amendment (the “Bylaws Amendment”) to the Amended and Restated Bylaws of the Company, as amended (the “Bylaws”), effective immediately. | d341363d8k.htm |
| 2022-03-08 | 8-K | 2022-03-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of March 8, 2022, the Board of Directors (the “Board”) of Biocept, Inc. (the “Company”) appointed Philippe Marchand, Ph.D. to serve as the Company’s Chief Operations Officer. | d248454d8k.htm |
| 2022-02-16 | 8-K | 2022-02-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 15, 2022, (i) Michael W. Nall resigned from his position as the President and Chief Executive Officer, including as the principal executive officer, of Biocept, Inc. (the “Company”), and from the Company’s Board of Directors (the “Board”), effective as of the close of business on February 15, 2022, and (ii) Timothy C. Kennedy resigned from his positions as the Chief Financial Officer, Chief Operating Officer and Secretary, including as the principal financial officer and principal accounting officer, of the Company, effective as of the close of business on February 15, 2022. | d313469d8k.htm |
| 2022-01-31 | 8-K | 2022-01-25 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On January 25, 2022, after consultation with its independent registered public accounting firm, Mayer Hoffman McCann P.C., Biocept, Inc. (the “Company”) determined that the Company’s unaudited interim condensed financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021(the “Relevant Financial Statements”) can no longer be relied upon. | bioc-8k_20220125.htm |